CN106620660A - Bleeding-stopping spray - Google Patents
Bleeding-stopping spray Download PDFInfo
- Publication number
- CN106620660A CN106620660A CN201611258274.6A CN201611258274A CN106620660A CN 106620660 A CN106620660 A CN 106620660A CN 201611258274 A CN201611258274 A CN 201611258274A CN 106620660 A CN106620660 A CN 106620660A
- Authority
- CN
- China
- Prior art keywords
- parts
- bleeding
- stopping
- marine alga
- haemostatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Abstract
The invention relates to the field of biological medicines, in particular to a bleeding-stopping spray. The bleeding-stopping spray is prepared from, by mass, 1-98 parts of water, 1-20 parts of seaweed eucheuma extract and 1-5 parts of fibrinogen. Due to the fact that a novel water-soluble bleeding-stopping factor is adopted in the bleeding-stopping spray in the scheme, liquification of the bleeding-stopping spray is achieved, and the liquified bleeding-stopping spray can well penetrate into wounds and other parts needing bleeding-stopping and plays a good bleeding-stopping effect. The bleeding-stopping spray provided in the scheme combines with physical bleeding stopping based on biological-chemical bleeding stopping, meanwhile provides multiple anti-inflammation and sterilizing factors and can prevent infection and promote heating.
Description
Technical field
The present invention relates to biomedicine field, more particularly to a kind of haemostatic sprays.
Background technology
Blood is the necessary material of people living, but runs into fortuitous event in daily life sometimes, for example, cut the dish not little
It is anxious in one's hands or by sharp weapon scratch etc., cause human body wound and massive blood loss occur, if stopping blooding meeting not in time in this case
So that the condition of the injury of the wounded further deteriorates, or even death can be caused.Therefore first aid hemostasis and prevention infection one are to all by the world
The attention of various countries' medical circle.
The effective ingredient of existing hemostatic material is mainly gelatin and shitosan.Typical patented product has following several.
WO 01/28603 discloses a kind of injectable dosage formulations being related to for delivering composition, and said composition includes skeletonization
Albumen and hemostasis gelatin foam paste, the method for further relating to prepare the hemostasis gelatin foam paste for being adapted to injection BMP, the side
Method includes being hydrated Gelfoam powder with glutamate buffers.
It is related to skin biopsy tissue plug in the patents of US 5,394,886, wherein, the plug is to use many made by gelatin materials
Hole sponge, by it wound is implanted into, its expansion, absorbs blood, and can be completely absorbed in patient's body.It is related to perforator
(for cutting the blade of skin) and the combination of plunger.The plunger for being used can be by commercial channel acquisition
Gelfoam .Gelfoam is the product obtained by commercial channel, and it can provide powder gelatin, to answer as styptic
Used in bleeding surface.The powder gelatin is provided with the full glass jar with crown cap or pouch, respectively by it
Open, and by its receiving material, i.e. gelatin, in pouring sterile beaker or bowl into.
US 5,645,849 discloses hemostatic plaster, and it includes biodegradable gelatin substrate, promoting amount of stopping blooding it is solidifying
Hemase and EACA.
JP 62221357 discloses the skin ointments for promoting anastalsis, and it includes dissolving thermoplastic in a solvent
Property resin or rubber, and including scattered jelly powder.The product is to include thermoplastic resin or rubber, and collagen, gelatin or
The ointment of shitosan fine powder.
FR 2679772 is related to the granular materials for forming embolism, stops blooding or coagulant including scribbling
(thrombonicagent) polymer.The styptic can be jelly powder in small, broken bits.
US 6,096,309 is related to hemostatic composition, and it includes fibrin ferment and non-MC in aqueous medium
With the mixture of MC, wherein, the average fibril diameter of the MC is of about 3-30nm.
US 4,515,637 is related to prepare the method for collagen-fibrin ferment hemostatic composition, and is related to lyophilized collagen
Product, it includes collagen and fibrin ferment.
US 6,045,570 is related to be used as the jelly powder of styptic, and is related to biological sealer, and it includes gelatine size,
The gelatine size includes the gelatin powder for grinding.The slurry preferably includes Gelfoam powder, the powder be selected from salt solution
Mix with the diluent of water.The slurry shows outstanding flow performance, i.e., it shows the dilatancy of minimum
(dilatency), and can be by catheter lumen, particularly little chamber be easily injected or is imported.Therefore, the product has
Outstanding characteristic of fluid.
US 6,060,461 is related to particle, particularly glucan particles, and its granularity is 0.5-1000 μm, and averagely
Aperture is 0.5-1000 nm.This document disclose by the way that the particle is used in dry powder form on wound, can promote
Formation of the blood clotting on wound.
US 3,930,052 is related to varigrained cold water soluble gelatin composition.
US 5,225,536 is related to gelatin and amino acid granular.It has been said that such particle is adapted to and various mixed with resin.
The size distribution is such, and the granularity of most of particle is 1.5-9.0 μm.
US 2003/0012741 is related to the method for preparing micronizing collagen.It has been said that granularity should be less than 20 μm, with
Just the adhesive force to wound surface is optimized.
As can be seen here, the Main Ingredients and Appearance of existing hemostatic material is gelatin and shitosan, and main carriers form is hemostatic yarn
Cloth, stanch fibre band, tourniquet bandage.But, hemostatic gauze, stanch fibre band, tourniquet bandage are disadvantageous in that：Hemostasis
Time is longer, and the massive haemorrhage haemostatic effect in being particularly war wound and sudden accident to severe hemostasis is poor；It is easily viscous with wound
Even it is difficult dressing；Additionally, infection and suppuration of the above-mentioned hemostatic material to wound is helpless.
Although there are some haemostatic sprays in existing market, such as：
Traumacel S are the hemostasis sprinkling powders of pressure atomization dosage form formula, and active component is the hydrogen calcium salt of oxycellulose.
Traumacel P are powder styptics, and it includes the calcium salt (calcium carboxymethylcellulose) of oxycellulose,
It is used in dry powder form in bleeding part.
Avitene is microfibre (microfibullar) collagen hemostasis " powder ", is generally used in a dry form.
Arista is the haemostatic sprays for being based on microporous polysaccharide hemostatic ball (hemospheres),
Referring to US6,060,461.
But it can be seen that the essence or some short grained microspheres with solid of these sprays, and on-liquid microballoon.But
It is that for human internal environment, liquid hemostatic agent is more beneficial for hemostasis, thus, it is necessary to research and develop a kind of new liquid hemostatic
Agent.
The content of the invention
It is an object of the invention to provide a kind of haemostatic sprays, it is intended to which solution there are currently no asking for liquid hemostatic material
Topic.
What the present invention was realized in：A kind of haemostatic sprays, by the marine alga Extraction of Eucheuma gelatinae of mass fraction 1-98 parts；
The fibrinogen of mass fraction 1-5 parts and the water composition of remaining ingredient.Due to present invention employs a kind of new water solubility
Hemostatic factor, so the haemostatic sprays are liquid.
The present invention further technical scheme be：Also including the alkyl of 1-50 part percentage by weights.
The present invention further technical scheme be：Including the raw material of following percentage by weight：Marine alga Extraction of Eucheuma gelatinae 1-
20 parts, alkyl 10-25 parts；Fibrinogen 1-5 parts, remaining is water.
The present invention further technical scheme be：The marine alga Extraction of Eucheuma gelatinae includes algal polysaccharides 1-50 parts；Marine alga
Protein acid complex salt 1-20 part；Algin colloid 1-15 parts；Alginic acid fat 1-15 parts；Glue protein 1-96 parts.
The present invention further technical scheme be：The marine alga Extraction of Eucheuma gelatinae includes algal polysaccharides 20-49 parts；Marine alga
Protein acid complex salt 10-20 part；Algin colloid 2-15 parts；Alginic acid fat 5-15 parts；Glue protein 1-62 parts.
The present invention further technical scheme be：The marine alga Extraction of Eucheuma gelatinae includes algal polysaccharides 30-40 parts；Marine alga
Protein acid complex salt 10-20 part；Algin colloid 5-15 parts；Alginic acid fat 5-15 parts；Glue protein 10-49 parts.
The present invention further technical scheme be：Also include anti-inflammatory factors.The hemostasis is caused by adding anti-inflammatory factors
Gauze further realizes the effect of anti-inflammatory on the basis for realizing haemostatic effect.
The present invention further technical scheme be：The anti-inflammatory factors are selected from Nano Silver, aspirin, acetparaminosalol
One or more in sweet smell, Diclofenac, Indomethacin, brufen, fenbufen.
The present invention further technical scheme be：The anti-inflammatory factors are Nano Silver.
The present invention further technical scheme be：The concentration of the anti-inflammatory factors is 5-500 ppm.When being made using Nano Silver
For anti-inflammatory factors when nanometer silver concentration is set to play preferable effect for 5-500 ppm.
The invention has the beneficial effects as follows：As a result of a kind of new water solubility in the haemostatic sprays that this programme is provided
Hemostatic factor and realize the fluidization of haemostatic sprays, the haemostatic sprays of fluidization preferably penetrating wounds etc. can be needed
Where stopping blooding, more preferable haemostatic effect is played；The haemostatic sprays that this programme is provided are on the basis of biochemistry hemostasis
With reference to physics hemostasis, while providing various anti-inflammation and sterilization factors, infection is prevented from, promotes healing.
Specific embodiment
Present solution provides a kind of haemostatic sprays, by the marine alga Extraction of Eucheuma gelatinae of mass fraction 1-98 parts；Quality point
The fibrinogen of number 1-5 parts and the water composition of residual mass.Due to present invention employs a kind of new water miscible hemostasis
The factor, so the haemostatic sprays are liquid.
Preferably, the haemostatic sprays are also including the alkyl of 1-50 part percentage by weights.
The haemostatic sprays include the raw material of following percentage by weight：Water 50-97 parts；Marine alga Extraction of Eucheuma gelatinae 1-20
Part, alkyl 10-25 parts；Fibrinogen 1-5 parts.
The marine alga Extraction of Eucheuma gelatinae includes algal polysaccharides 1-50 parts；Extra large alginic acid complex salt 1-20 part；Algin colloid
1-15 parts；Alginic acid fat 1-15 parts；Glue protein 1-95 parts.
The marine alga Extraction of Eucheuma gelatinae includes algal polysaccharides 20-49 parts；Extra large alginic acid complex salt 10-20 part；Algin glue
Body 2-15 parts；Alginic acid fat 5-15 parts；With glue protein 1-62 parts.
The marine alga Extraction of Eucheuma gelatinae includes algal polysaccharides 30-40 parts；Extra large alginic acid complex salt 10-20 part；Algin glue
Body 5-15 parts；Alginic acid fat 5-15 parts；Kappaphycus alvarezi isomery polysaccharide 1-5 parts and glue protein 10-49 parts.
The haemostatic sprays also include anti-inflammatory factors.The hemostatic gauze is caused to realize stopping by adding anti-inflammatory factors
The effect of anti-inflammatory is further realized on the basis of blood effect.
The anti-inflammatory factors are selected from Nano Silver, aspirin, acetparaminosalol sweet smell, Diclofenac, Indomethacin, Bu Luo
One or more in fragrant, fenbufen.
The anti-inflammatory factors are Nano Silver.
The concentration of the anti-inflammatory factors is 5-500 ppm.By nanometer silver concentration when using Nano Silver as anti-inflammatory factors
It is set to that for 5-500 ppm preferable effect can be played.
The validity of the hemostatic gauze that this programme is provided is illustrated followed by experimental data.
Specific embodiment one：A kind of new haemostatic sprays.The spray contains 75% water（Mass percent, similarly hereinafter）,
10% marine alga Extraction of Eucheuma gelatinae, 5% fibrinogen, 10% alkyl.Wherein, it is extra large containing 40% in marine alga Extraction of Eucheuma gelatinae
Polysaccharides, 10% extra large alginic acid complex salt, 10% algin colloid, 10% alginic acid fat, 30% glue protein.Also it is containing concentration
The nano-silver ionic of 200 ppm.
Zoopery is carried out using above-mentioned haemostatic sprays, zoopery process is as follows：The black pig one of microspecies is chosen, with directly
The cone that 5 millimeters of footpath is pierced into 15 mm depths in experiment pig limb artery position, and blood ejection is checked whether there is after extracting, and confirms stream
Sprayed three times to wound in ten seconds with experimental products after blood, and the blood coagulation of O＆E wound and infiltration situation.
This experiment is first tested in left hind, according to above method, is made after wound with haemostatic sprays at ten seconds
It is interior that wound is sprayed three times, above-mentioned wound is as a result shown in 50-65 seconds intravascular coagulations and stop blooding, wound is no longer bled.
Then wound is done in right hind with same method, using pure water same operation is carried out as a control group, without observation
To haemostatic effect.
Carry out repeating experiment from the black pig of many microspecies, experimental result can repeat.Demonstrate the haemostatic sprays certain
With effect.
Specific embodiment two：A kind of new haemostatic sprays.The spray contains 50% water（Mass percent, similarly hereinafter）,
20% marine alga Extraction of Eucheuma gelatinae, 5% fibrinogen, 25% alkyl.Wherein, it is extra large containing 10% in marine alga Extraction of Eucheuma gelatinae
Polysaccharides, 20% extra large alginic acid complex salt, 15% algin colloid, 15% alginic acid fat, 40% glue protein.Also it is containing concentration
The nano-silver ionic of 500 ppm.
The above-mentioned zoopery of repetition, as a result finds that experimental group there occurs blood coagulation, control group in 60 seconds（Pure water）At 60 seconds
It is interior cannot blood coagulation.
Specific embodiment three：A kind of new haemostatic sprays.The spray contains 98% water（Mass percent, similarly hereinafter）,
1% marine alga Extraction of Eucheuma gelatinae, 1% fibrinogen, without alkyl.Wherein, it is extra large containing 1% in marine alga Extraction of Eucheuma gelatinae
Polysaccharides, 1% extra large alginic acid complex salt, 1% algin colloid, 1% alginic acid fat, 95% glue protein.It is 10 also containing concentration
The nano-silver ionic of ppm.
The above-mentioned zoopery of repetition, as a result finds that experimental group there occurs blood coagulation, control group in 120 seconds（Pure water）120
Cannot blood coagulation in second.
Specific embodiment four：A kind of new haemostatic sprays.The spray contains 1% water（Mass percent, similarly hereinafter）,
94% marine alga Extraction of Eucheuma gelatinae, 5% fibrinogen, 1% alkyl.Wherein, it is extra large containing 50% in marine alga Extraction of Eucheuma gelatinae
Polysaccharides, 1% extra large alginic acid complex salt, 1% algin colloid, 1% alginic acid fat, 47% glue protein.It is 100 also containing concentration
The nano-silver ionic of ppm.
The above-mentioned zoopery of repetition, as a result finds that experimental group there occurs blood coagulation, control group in 30 seconds（Pure water）At 30 seconds
It is interior cannot blood coagulation.
Realize as a result of a kind of new water miscible hemostatic factor in the haemostatic sprays that this programme is provided
The fluidization of haemostatic sprays, the haemostatic sprays of fluidization preferably penetrating wounds etc. can be needed where hemostasis, played
More preferable haemostatic effect；The haemostatic sprays that this programme is provided stop blooding on the basis of biochemistry hemostasis with reference to physics, while
Various anti-inflammation and sterilization factors are provided, infection is prevented from, promote healing.
Presently preferred embodiments of the present invention is the foregoing is only, not to limit the present invention, all essences in the present invention
Any modification, equivalent and improvement made within god and principle etc., should be included within the scope of the present invention.
Claims (10)
1. a kind of haemostatic sprays, it is characterised in that：By the marine alga Extraction of Eucheuma gelatinae of mass fraction 1-98 parts；Mass fraction 1-
5 parts of fibrinogen and the water composition of remaining ingredient.
2. haemostatic sprays according to claim 1, it is characterised in that：Also including the alkyl of 1-50 part percentage by weights.
3. haemostatic sprays according to claim 2, it is characterised in that：Including the raw material of following percentage by weight：Marine alga
Extraction of Eucheuma gelatinae 1-20 parts, alkyl 10-25 parts；Fibrinogen 1-5 parts, remaining is water.
4. according to arbitrary described haemostatic sprays in claim 1-3, it is characterised in that：The marine alga Extraction of Eucheuma gelatinae bag
Include algal polysaccharides 1-50 parts；Extra large alginic acid complex salt 1-20 part；Algin colloid 1-15 parts；Alginic acid fat 1-15 parts；Glue protein 1-96
Part.
5. haemostatic sprays according to claim 4, it is characterised in that：The marine alga Extraction of Eucheuma gelatinae includes that marine alga is more
Sugared 20-49 parts；Extra large alginic acid complex salt 10-20 part；Algin colloid 2-15 parts；Alginic acid fat 5-15 parts；Kappaphycus alvarezi isomery
Polysaccharide 1-5 parts and glue protein 1-62 parts.
6. haemostatic sprays according to claim 5, it is characterised in that：The marine alga Extraction of Eucheuma gelatinae includes that marine alga is more
Sugared 30-40 parts；Extra large alginic acid complex salt 10-20 part；Algin colloid 5-15 parts；Alginic acid fat 5-15 parts；Kappaphycus alvarezi isomery
Polysaccharide 1-5 parts and glue protein 10-49 parts.
7. according to arbitrary described haemostatic sprays in claim 1-3, it is characterised in that：Also include anti-inflammatory factors.
8. haemostatic sprays according to claim 7, it is characterised in that：The anti-inflammatory factors are selected from Nano Silver, Ah Si
One or more in woods, acetparaminosalol sweet smell, Diclofenac, Indomethacin, brufen, fenbufen.
9. haemostatic sprays according to claim 8, it is characterised in that：The anti-inflammatory factors are Nano Silver.
10. haemostatic sprays according to claim 9, it is characterised in that：The concentration of the anti-inflammatory factors is 5-500
ppm。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611258274.6A CN106620660A (en) | 2016-12-30 | 2016-12-30 | Bleeding-stopping spray |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611258274.6A CN106620660A (en) | 2016-12-30 | 2016-12-30 | Bleeding-stopping spray |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106620660A true CN106620660A (en) | 2017-05-10 |
Family
ID=58837627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611258274.6A Pending CN106620660A (en) | 2016-12-30 | 2016-12-30 | Bleeding-stopping spray |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106620660A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000229882A (en) * | 1998-12-10 | 2000-08-22 | Sankyo Co Ltd | Modified cyclodextrin-containing thrombin aqueous liquid preparation |
| WO2001062278A1 (en) * | 2000-02-22 | 2001-08-30 | Hogy Medical Co. Ltd. | Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same |
| CN101084022A (en) * | 2004-10-20 | 2007-12-05 | 伊西康公司 | Absorbable hemostat |
| CN101184513A (en) * | 2004-12-13 | 2008-05-21 | 东南医疗技术有限公司 | Agents for controlling biological fluids and methods of use thereof |
| WO2008081463A2 (en) * | 2007-01-04 | 2008-07-10 | Hepacore Ltd. | Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof |
| CN101490029A (en) * | 2006-07-18 | 2009-07-22 | 安泰碧治疗公司 | 4-hydroxythiobenzamide derivatives of drugs |
| CN103717208A (en) * | 2011-07-06 | 2014-04-09 | 普罗菲布瑞克斯公司 | Formulations for wound therapy |
| WO2016100861A1 (en) * | 2014-12-19 | 2016-06-23 | Baxter International, Inc. | Flowable hemostatic composition |
-
2016
- 2016-12-30 CN CN201611258274.6A patent/CN106620660A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000229882A (en) * | 1998-12-10 | 2000-08-22 | Sankyo Co Ltd | Modified cyclodextrin-containing thrombin aqueous liquid preparation |
| WO2001062278A1 (en) * | 2000-02-22 | 2001-08-30 | Hogy Medical Co. Ltd. | Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same |
| CN101084022A (en) * | 2004-10-20 | 2007-12-05 | 伊西康公司 | Absorbable hemostat |
| CN101184513A (en) * | 2004-12-13 | 2008-05-21 | 东南医疗技术有限公司 | Agents for controlling biological fluids and methods of use thereof |
| CN101490029A (en) * | 2006-07-18 | 2009-07-22 | 安泰碧治疗公司 | 4-hydroxythiobenzamide derivatives of drugs |
| WO2008081463A2 (en) * | 2007-01-04 | 2008-07-10 | Hepacore Ltd. | Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof |
| CN103717208A (en) * | 2011-07-06 | 2014-04-09 | 普罗菲布瑞克斯公司 | Formulations for wound therapy |
| WO2016100861A1 (en) * | 2014-12-19 | 2016-06-23 | Baxter International, Inc. | Flowable hemostatic composition |
Non-Patent Citations (10)
| Title |
|---|
| EKATERINA V. SOKOLOVA等: "Influence of red algal sulfated polysaccharides on blood coagulation and platelets activation in vitro", 《J BIOMED MATER RES PART A》 * |
| HEE-KEONGTONG等: "The molecular weight and viscosity of the water-soluble polysaccharide(s) from Eucheuma spinosum", 《CARBOHYDRATE RESEARCH》 * |
| SAMANEH GHASEMI FARD等: "Wound healing properties of Eucheuma cottonii extracts in Sprague-Dawley rats", 《JOURNAL OF MEDICINAL PLANTS RESEARCH》 * |
| 孙秀发等: "《食品营养学》", 31 July 2011, 郑州大学出版社 * |
| 张小铭等: "《临床疼痛病中西医结合治疗》", 30 September 2008, 科学技术文献出版社 * |
| 张惟杰等: "《复合多糖生化研究技术》", 31 December 1987, 上海科学技术出版社 * |
| 戴德银: "《实用新药特药手册》", 31 May 2012, 人民军医出版社 * |
| 王艳: "《藻类植物》", 31 July 2013, 吉林出版集团有限责任公司 * |
| 顾其胜: "《海藻酸盐基生物医用材料与临床医学》", 30 April 2015, 上海科学技术出版社 * |
| 马世昌: "《化学物质辞典》", 30 April 1999, 陕西科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2829305C (en) | Haemostatic material | |
| US9408913B2 (en) | Composition and dressing for wound treatment | |
| EP2233157A1 (en) | A biocompatible denatured starch sponge material | |
| JP2016074673A (en) | Dry powder fibrin sealant | |
| JP2003531850A (en) | Hemostatic, blood coagulant application method, blood coagulant base | |
| WO2013048787A1 (en) | Novel hemostatic compositions and dressings for bleeding | |
| US10022411B2 (en) | Hemostatic preparation containing an extract of golden moss | |
| Mercy et al. | Chitosan-derivatives as hemostatic agents: Their role in tissue regeneration | |
| CN105056285B (en) | It is a kind of can adhesion organization crack growth factor combine dressing and preparation method thereof | |
| CN111954545A (en) | Method for preparing hemostatic composition | |
| JP7378486B2 (en) | Medical adhesives, their preparation methods, and their uses | |
| JP2021502154A (en) | Hemostatic pastes and delivery devices with hemostatic promoter-enriched surfaces | |
| CN108498855A (en) | A kind of antibacterial anti hemorrhagic colloidal sol and preparation method thereof | |
| US11357883B1 (en) | Method for preparing absorbable haemostatic composition for body and haemostatic composition prepared thereby | |
| CN106620660A (en) | Bleeding-stopping spray | |
| CN112300418B (en) | Adhesive high-efficiency hemostatic microsphere and preparation method thereof | |
| CN108261560A (en) | A kind of degradable absorption hemostatic material of grain containing modified starch nano and its application | |
| TR201804823T1 (en) | HEMOSTATIC COMPOSITION | |
| WO2021176457A1 (en) | Anti-hemorrhaging compositions | |
| CN106860907B (en) | A kind of hemostatic gauze | |
| CN112717195B (en) | Biodegradable rapid hemostatic granule and preparation method thereof | |
| CN109568635B (en) | In-situ expansion high-water-absorption hemostatic material and preparation method thereof | |
| KR20240002278A (en) | Fiber Mixed Chitosan Foam Hemostatic Material And Manufacturing Method Thereof | |
| CN102266581A (en) | Absorbable hemostatic sealing material and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170510 |